BCR-ABL-IN-9_product_DataBase

CAS: F: C22H20N4O3 W: 388.42

BCR-ABL-IN-9 (Compound B1) is a BCR-ABL inhibitor that achieves sustained BCR-ABL suppression by forming stable covalent

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	BCR-ABL-IN-9 (Compound B1) is a BCR-ABL inhibitor that achieves sustained BCR-ABL suppression by forming stable covalent bonds with the ABL kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the ABL kinase (IC50 = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity[1].
Formula	C22H20N4O3
Molar Mass	388.42
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Sun J, et al. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies[J]. Journal of Advanced Research, 2024.

PeptideDB